This company has been acquired
Reata Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Reata Pharmaceuticals's earnings have been declining at an average annual rate of -17.3%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 44.5% per year.
Key information
-17.3%
Earnings growth rate
-12.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -44.5% |
| Return on equity | -100.4% |
| Net Margin | -373.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
May 10
FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug
Oct 13Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?
Oct 12Reata Pharmaceuticals Q2 2022 Earnings Preview
Aug 05We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth
Jun 22Reata Pharmaceuticals: Once Beaten, Twice Shy
Mar 28Reata's Advisory Committee Hiccup Ruins Its Future Prospects
Dec 31Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
Dec 23Revenue & Expenses BreakdownBeta
How Reata Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 23 | -88 | 160 | 0 |
| 31 Mar 23 | 1 | -354 | 139 | 0 |
| 31 Dec 22 | 2 | -312 | 109 | 0 |
| 30 Sep 22 | 3 | -312 | 108 | 0 |
| 30 Jun 22 | 10 | -305 | 106 | 0 |
| 31 Mar 22 | 11 | -304 | 103 | 0 |
| 31 Dec 21 | 11 | -297 | 99 | 0 |
| 30 Sep 21 | 14 | -278 | 88 | 0 |
| 30 Jun 21 | 8 | -271 | 80 | 0 |
| 31 Mar 21 | 9 | -266 | 75 | 0 |
| 31 Dec 20 | 9 | -248 | 75 | 0 |
| 30 Sep 20 | 8 | -369 | 78 | 0 |
| 30 Jun 20 | 15 | -343 | 74 | 0 |
| 31 Mar 20 | 20 | -310 | 69 | 0 |
| 31 Dec 19 | 27 | -290 | 58 | 0 |
| 30 Sep 19 | 32 | -129 | 44 | 0 |
| 30 Jun 19 | 30 | -120 | 37 | 0 |
| 31 Mar 19 | 29 | -114 | 36 | 0 |
| 31 Dec 18 | 54 | -81 | 33 | 0 |
| 30 Sep 18 | 55 | -72 | 31 | 0 |
| 30 Jun 18 | 62 | -53 | 29 | 0 |
| 31 Mar 18 | 67 | -36 | 25 | 0 |
| 31 Dec 17 | 48 | -48 | 23 | 0 |
| 30 Sep 17 | 50 | -35 | 22 | 0 |
| 30 Jun 17 | 50 | -24 | 20 | 0 |
| 31 Mar 17 | 50 | -13 | 19 | 0 |
| 31 Dec 16 | 50 | -6 | 17 | 0 |
| 30 Sep 16 | 50 | -4 | 16 | 0 |
| 30 Jun 16 | 50 | -2 | 15 | 0 |
| 31 Mar 16 | 50 | -3 | 14 | 0 |
| 31 Dec 15 | 50 | -1 | 14 | 0 |
| 30 Sep 15 | 50 | 0 | 13 | -25 |
| 30 Jun 15 | 51 | 0 | 12 | 0 |
| 31 Mar 15 | 51 | 2 | 12 | 0 |
| 31 Dec 14 | 51 | 1 | 12 | 0 |
| 31 Dec 13 | 51 | -36 | 12 | 40 |
Quality Earnings: RETA is currently unprofitable.
Growing Profit Margin: RETA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RETA is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare RETA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RETA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: RETA has a negative Return on Equity (-100.38%), as it is currently unprofitable.